Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis - 22/12/17

Doi : 10.1016/S1473-3099(17)30592-3

Philipp Schuetz, ProfMD ^a,^b,^{^{†
Contributed equally as first authors},}^⁎ , Yannick Wirz, MD ^a,^{^{†
Contributed equally as first authors}}, Ramon Sager, MD ^a,^{^{†
Contributed equally as first authors}}, Mirjam Christ-Crain, MD ^b,^c, Daiana Stolz, MD ^b,^d, Michael Tamm, MD ^b,^d, Lila Bouadma, MD ^f, Charles E Luyt, MD ^g, Michel Wolff, MD ^f, Jean Chastre, MD ^g, Florence Tubach, ProfMD ^h, Kristina B Kristoffersen, MD ⁱ, Olaf Burkhardt, MD ^j, Tobias Welte, ProfMD ^j, Stefan Schroeder, ProfMD ^k, Vandack Nobre, MD ^l, Long Wei, MD ^m, Heiner C Bucher, MD ^b,^e, Djillali Annane, MD ⁿ, Konrad Reinhart, ProfMD ^o, Ann R Falsey, MD ^p, Angela Branche, ProfMD ^p, Pierre Damas, MD ^q, Maarten Nijsten, MD ^r, Dylan W de Lange, MD ^s, Rodrigo O Deliberato, MD ^t, Carolina F Oliveira, MD ^u, Vera Maravić-Stojković, MD ^v, Alessia Verduri, MD ^w, Bianca Beghé, MD ^w, Bin Cao, MD ^x, Yahya Shehabi, ProfPhD ^y,^z, Jens-Ulrik S Jensen, MD ^aa, Caspar Corti, MD ^ab, Jos A H van Oers, MD ^ac, Albertus Beishuizen, MD ^ad, Armand R J Girbes, MD ^ae, Evelien de Jong, MD ^ae, Matthias Briel, MD ^b,^e,^af,^{^{†
Contributed equally as first authors}}, Beat Mueller, ProfMD ^a,^b

^a Medical University Department, Kantonsspital Aarau, Aarau, Switzerland

^b Faculty of Medicine, University of Basel, Basel, Switzerland

^c Division of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Basel, Basel, Switzerland

^d Clinic of Pneumology and Pulmonary Cell Research, University Hospital Basel, Basel, Switzerland

^e Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland

^f Service de Réanimation Médicale, Université Paris 7-Denis-Diderot, Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France

^g Service de Réanimation Médicale, Université Paris 6-Pierre-et-Marie-Curie, Paris, France

^h Département de Biostatistique, Santé publique et Information médicale, AP-HP, Hôpital Pitié-Salpêtrière, Université Pierre et Marie Curie, Sorbonne Universités, Paris, France

ⁱ Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark

^j Department of Pulmonary Medicine, Medizinische Hochschule Hannover, Member of the German Center of Lung Research, Hannover, Germany

^k Department of Anesthesiology and Intensive Care Medicine, Krankenhaus Dueren, Dueren, Germany

^l Department of Intensive Care, Hospital das Clinicas da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

^m Department of Internal and Geriatric Medicine, Shanghai Jiao Tong University, Affiliated Sixth People’s Hospital, Shanghai, China

ⁿ Critical Care Department, Hôpital Raymond Poincaré, AP-HP, Faculty of Health Science Simone Veil, UVSQ–University Paris Saclay, Garches, France

^o Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany

^p Department of Medicine, University of Rochester, Rochester, NY, USA

^q Department of General Intensive Care, University Hospital of Liege, Domaine Universitaire de Liège, Liège, Belgium

^r University Medical Centre, University of Groningen, Groningen, Netherlands

^s University Medical Center Utrecht and University of Utrecht, Utrecht, Netherlands

^t Critical Care Unit, Hospital Israelita Albert Einstein, São Paulo, Brazil

^u Department of Internal Medicine, School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

^v Immunology Laboratory, Dedinje Cardiovascular Institute, Belgrade, Serbia

^w Section of Respiratory Medicine, Department of Medical and Surgical Sciences, University Polyclinic of Modena, University of Modena and Reggio Emilia, Modena, Italy

^x Center for Respiratory Diseases, Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China

^y Critical Care and Peri-operative Medicine, Monash Health, Melbourne, VIC, Australia

^z School of Clinical Sciences, Faculty of Medicine Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia

^aa Centre of Excellence for Health, Immunity and Infections, Department of Infectious Diseases and Rheumatology, Finsencentret, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

^ab Department of Respiratory Medicine, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark

^ac Elisabeth Tweesteden Hospital, Tilburg, Netherlands

^ad Medisch Spectrum Twente, Enschede, Netherlands

^ae VUmc University Medical Center, Amsterdam, Netherlands

^af Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada

^* Correspondence to: Prof Philipp Schuetz, University Department of Medicine, Kantonsspital Aarau, CH-5001 Aarau, Switzerland Correspondence to: Prof Philipp Schuetz, University Department of Medicine Kantonsspital Aarau Aarau CH-5001 Switzerland

Summary

Background

In February, 2017, the US Food and Drug Administration approved the blood infection marker procalcitonin for guiding antibiotic therapy in patients with acute respiratory infections. This meta-analysis of patient data from 26 randomised controlled trials was designed to assess safety of procalcitonin-guided treatment in patients with acute respiratory infections from different clinical settings.

Methods

Based on a prespecified Cochrane protocol, we did a systematic literature search on the Cochrane Central Register of Controlled Trials, MEDLINE, and Embase, and pooled individual patient data from trials in which patients with respiratory infections were randomly assigned to receive antibiotics based on procalcitonin concentrations (procalcitonin-guided group) or control. The coprimary endpoints were 30-day mortality and setting-specific treatment failure. Secondary endpoints were antibiotic use, length of stay, and antibiotic side-effects.

Findings

We identified 990 records from the literature search, of which 71 articles were assessed for eligibility after exclusion of 919 records. We collected data on 6708 patients from 26 eligible trials in 12 countries. Mortality at 30 days was significantly lower in procalcitonin-guided patients than in control patients (286 [9%] deaths in 3336 procalcitonin-guided patients vs 336 [10%] in 3372 controls; adjusted odds ratio [OR] 0·83 [95% CI 0·70 to 0·99], p=0·037). This mortality benefit was similar across subgroups by setting and type of infection (p_interactions>0·05), although mortality was very low in primary care and in patients with acute bronchitis. Procalcitonin guidance was also associated with a 2·4-day reduction in antibiotic exposure (5·7 vs 8·1 days [95% CI −2·71 to −2·15], p<0·0001) and a reduction in antibiotic-related side-effects (16% vs 22%, adjusted OR 0·68 [95% CI 0·57 to 0·82], p<0·0001).

Interpretation

Use of procalcitonin to guide antibiotic treatment in patients with acute respiratory infections reduces antibiotic exposure and side-effects, and improves survival. Widespread implementation of procalcitonin protocols in patients with acute respiratory infections thus has the potential to improve antibiotic management with positive effects on clinical outcomes and on the current threat of increasing antibiotic multiresistance.

Funding

National Institute for Health Research.

Le texte complet de cet article est disponible en PDF.

Plan

Introduction

Methods

Search strategy and selection criteria

Data analysis

Role of the funding source

Results

Discussion

Export

Vol 18 - N° 1

P. 95-107 - janvier 2018 Retour au numéro

Article précédent

Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation
Valentina Cambiano, Alec Miners, David Dunn, Sheena McCormack, Koh Jun Ong, O Noel Gill, Anthony Nardone, Monica Desai, Nigel Field, Graham Hart, Valerie Delpech, Gus Cairns, Alison Rodger, Andrew N Phillips

| Article suivant

Prolonged versus short-term intravenous infusion of antipseudomonal ?-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials
Konstantinos Z Vardakas, Georgios L Voulgaris, Athanasios Maliaros, George Samonis, Matthew E Falagas

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis - 22/12/17

Summary

Background

Methods

Findings

Interpretation

Funding

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL